Trade Summary

3 days ago, Wang Lai, serving as President, Global Head of R&D at BeOne Medicines Ltd. (ONC), sold 1,367 shares at $269.38 per share, for a total transaction value of $368,246.83.

This sale represents a 100.00% decrease in Wang Lai's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Monday, June 8, 2026 and publicly disclosed via SEC Form 4 filing on Wednesday, June 10, 2026 at 5:25 PM ET, 2 days after the trade was made.

BeOne Medicines Ltd. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.